Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Common Equity: 2016-2021

Historic Common Equity for ENDRA Life Sciences (NDRA) over the last 5 years, with Sep 2021 value amounting to $13.2 million.

  • ENDRA Life Sciences' Common Equity rose 294.49% to $13.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $13.2 million, marking a year-over-year increase of 294.49%. This contributed to the annual value of $7.2 million for FY2020, which is 50.59% up from last year.
  • As of Q3 2021, ENDRA Life Sciences' Common Equity stood at $13.2 million, which was down 12.23% from $15.0 million recorded in Q2 2021.
  • ENDRA Life Sciences' 5-year Common Equity high stood at $17.9 million for Q1 2021, and its period low was -$1.4 million during Q1 2017.
  • Its 3-year average for Common Equity is $6.5 million, with a median of $3.8 million in 2019.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 106.38% in 2018, then spiked by 1,434.47% in 2021.
  • Over the past 5 years, ENDRA Life Sciences' Common Equity (Quarterly) stood at $5.3 million in 2017, then rose by 18.44% to $6.2 million in 2018, then declined by 23.81% to $4.8 million in 2019, then surged by 50.59% to $7.2 million in 2020, then soared by 294.49% to $13.2 million in 2021.
  • Its last three reported values are $13.2 million in Q3 2021, $15.0 million for Q2 2021, and $17.9 million during Q1 2021.